Millions of Americans suffer from sleep apnea, but bringing a CPAP machine can be a little difficult, especially if you're ...

IXHL Stock - Incannex Healthcare’s shares surged 876% after completing patient dosing in the Phase 2 trial of its oral sleep ...

Incannex Healthcare Inc IXHL +854.6% + Free Alerts shares surged 876% to 83 cents on Wednesday after the company announced ...

Tirzepatide is now approved for the treatment of obstructive sleep apnea, highlighting the drug class' potential in sleep ...

Q2 2025 Earnings Call Transcript May 13, 2025 Operator: Thank you for standing by. This is the conference operator. Welcome ...

Patient dosing completed in Phase 2 portion of Phase 2/3 RePOSA study evaluating IHL-42X oral treatment for OSA.End-of-study follow-up assessments on track for completion by May 17, 2025.Topline ...

The Oral Appliances market is expected to grow from an estimated USD 310.1 billion in 2024 to USD 510.7 billion in 2033, at a CAGR of 5.70%. VANCOUVER, BC, CANADA, May 14, 2025 /EINPresswire.com/ -- ...

CLEARWATER, FL / ACCESS Newswire / May 13, 2025 / REMSleep Holdings, Inc. (OTC PINK:RMSL) Enters into Formal Agreement with , a major DME distributor. The DeltaWave is now available nationwide. Tom ...

New smart sensors claim to improve responsiveness and long-term sleep health by integrating snore detection capability into ...

Superior Sensor Technology says the new CP203 and CP303 enhance sleep apnea therapy with built-in snore detection.

A study has found that moderate-to-severe obstructive sleep apnea increases risk for incident myocardial infarction between 12 and 5:59 AM.